BioVie Inc., a Nevada-based biopharmaceutical company, has filed an amended Form 8-K/A with the Securities and Exchange Commission (SEC) on September 24, 2024. The amendment pertains to a previously filed report regarding the company's entry into a placement agent agreement with ThinkEquity LLC. This agreement is in connection with the issuance and sale of up to 1,960,800 shares of BioVie's class A common stock at $1.53 per share and/or pre-funded warrants to purchase common stock at $1.5299 per warrant, along with common stock purchase warrants to purchase an equal number of shares. The amendment was filed to include an amended Exhibit 5.1, which is the legal opinion of Fennemore Craig, P.C. No other changes were made to the original Form 8-K. The exhibits attached to the amendment include forms of the pre-funded and common warrants, the placement agent's warrant agreement, legal opinions, and consents from legal firms, as well as press releases dated September 23, 2024.

BioVie Inc., a Nevada-based biopharmaceutical company, has filed an amended Form 8-K/A with the Securities and Exchange Commission (SEC) on September 24, 2024. The amendment pertains to a previously filed report regarding the company's entry into a placement agent agreement with ThinkEquity LLC. This agreement is in connection with the issuance and sale of up to 1,960,800 shares of BioVie's class A common stock at $1.53 per share and/or pre-funded warrants to purchase common stock at $1.5299 per warrant, along with common stock purchase warrants to purchase an equal number of shares. The amendment was filed to include an amended Exhibit 5.1, which is the legal opinion of Fennemore Craig, P.C. No other changes were made to the original Form 8-K. The exhibits attached to the amendment include forms of the pre-funded and common warrants, the placement agent's warrant agreement, legal opinions, and consents from legal firms, as well as press releases dated September 23, 2024.